HSP90 is an abundant protein in Leishmania parasites that plays a major role in the parasite survival under stress conditions. Here we found that the HSP90 inhibitor 17-AAG (≥100 nM 17-AAG) induced cell cycle arrest at G 0 /G 1 in L. infantum and L. panamensis promastigotes, and highly potentiated the induction of cell death by an apoptotic-like process mediated by the ether phospholipid edelfosine (5-20 μM). These data suggest that the combined treatment of 17-AAG and edelfosine might be a novel and effective approach of combination therapy in the treatment of leishmaniasis.
Introduction
The current therapy of leishmaniasis, caused by the protozoan parasite Leishmania, includes a rather small number of drugs and is not satisfactory. The emergence of drug resistance and toxicity urges the identification of new targets and drugs in the treatment of this disease.
Heat shock proteins (HSPs) comprise several highly conserved families of protein folding facilitators that play important roles in the maintenance of cell functionality and in stress cell response, with HSP90 being of particular impact in the regulation of key steps in a multitude of biological processes (Queitsch et al., 2002; Whitesell and Lindquist, 2005) . HSP83, the Leishmania ortholog of the human HSP90, is highly and constitutively expressed in Leishmania spp., where represents about 2.8% of the total cell protein (Brandau et al., 1995) . Amino acid sequence alignment analysis shows high level of identity of the HSP90 proteins of L. braziliensis, L. major and L. donovani (~93%), which in turn show ~63% identity with human HSP90 (Silva et al., 2013) . L. infantum JPCM5 HSP83 protein (NCBI Reference Sequence: XP_003392729.1) (Peacock et al., 2007) shows 62% identity and 78% similarity with human HSP90 (GenBank: AAA36025.1) (Rebbe et al., 1987) by BLAST analysis, thus suggesting that Leishmania HSP83 might exert a similar function as human HSP90. In mammalian cells, HSP90 is involved in the stabilization and correct folding of a number of different client proteins, many of them playing a major role in cell survival, cell proliferation, and cancer cell growth (Whitesell and Lindquist, 2005) . In this regard, HSP90 has become a valuable target in cancer chemotherapy as its inhibition promotes proteasomal degradation of client proteins required for tumor cell survival (Whitesell and Lindquist, 2005) . Despite HSP90 is promiscuous in its action, and therefore caution should be taken into account to avoid undesired effects on chemotherapy (Nieto-Miguel et al., 2008) , a wide number of studies have shown that HSP90 inhibitors enhance the cytotoxic action of some anticancer drugs (George et al., 2005; Neckers, 2002) .
Similarly, inhibition of HSP90 in Leishmania parasites using specific inhibitors, such as geldanamycin, radicicol and 17-N-allylamino-17-demethoxygeldanamycin (17-AAG, tanespimycin) has been shown to affect transformation of promastigotes into rounded amastigote-like forms and to kill intracellular amastigotes (Li et al., 2009; Petersen et al., 2012; Wiesgigl and Clos, 2001a) . These data suggest that HSP90 inhibition might be a new therapeutic approach in the treatment of leishmaniasis.
On the other hand, the ether lipid edelfosine (1-O-octadecyl-2-O-methyl-racglycero-3-phosphocholine), a rather selective antitumor drug that acts at the cell membrane level (Gajate et al., 2004; Gajate and Mollinedo, 2007; Mollinedo et al., 2010a) , exerts in vitro antiparasitic activity against different species of Leishmania (Azzouz et al., 2006; Azzouz et al., 2005; Croft et al., 2003; Lux et al., 2000) . Furthermore, we have recently found following in vitro and in vivo studies that edelfosine represents a promising drug against leishmaniasis, killing Leishmania parasites through an apoptosis-like process (Varela-M et al., 2012) . In our previous study (Varela-M et al., 2012) , we found striking differences in the sensitivity of promastigotes from different species of Leishmania to edelfosine, including sensitive promastigotes, such as L. panamensis, and rather resistant ones, such as L. infantum. On these grounds, we analyzed here whether the combination of the HSP90 inhibitor 17-AAG (tanespimycin), currently in clinical trials as an antitumor agent (Katragadda et al., 2013; Neckers and Workman, 2012) , and edelfosine could improve the antileishmanial activity of the ether lipid.
Materials and methods

Drugs
Edelfosine was from R. Berchtold (Biochemisches Labor, Bern, Switzerland). Stock sterile solution of edelfosine (2 mM) was prepared as previously described (Mollinedo et al., 1997) 
Leishmania cells and culture conditions
The following Leishmania strains were used in this study: L. infantum (MCAN/ES/96/BCN150) and L. panamensis (MHOM/CO/87/UA140). Leishmania promastigotes were grown in RPMI-1640 culture medium, supplemented with 10% growth phase (1.5 or 2 x 10 6 parasites/ml) at 26ºC.
Growth inhibition assay
The inhibition of promastigote growth was determined by using the XTT (sodium 3,3'- Measurements were done in triplicate.
Analysis of apoptosis-like cell death by flow cytometry
Leishmania spp. promastigotes were treated for different times in the absence and in the presence of the indicated concentrations of 17-AAG at 26ºC. Edelfosine was then used at the indicated concentrations for 24 h. In combination therapies, 17-AAG was preincubated for 1 h before adding edelfosine. Thus, promastigotes were untreated or treated with different concentrations of 17-AAG for 1 h, and then incubated in the absence or presence of edelfosine for 24 h in combined treatments. Then, parasites were pelleted by centrifugation (1000 x g) for 6 min, and analyzed for apoptosis-like DNA breakdown by flow cytometry following a protocol previously described (Gajate et al., 2000) . Quantitation of apoptotic-like cells was monitored as the percentage of cells in the sub-G 0 /G 1 region (hypodiploidy) in cell cycle analysis, using a fluorescenceactivated cell sorting (FACS)Calibur flow cytometer (Becton Dickinson, San Jose, CA) equipped with a 488 nm argon laser. WinMDI 2.8 software was used for data analysis.
In addition, photographs of untreated and drug-treated parasites, before starting their preparation for flow cytometry assays, were taken using a Zeiss Axioplan microscope (Carl Zeiss GmbH, Oberkochen, Germany) at 40X magnification.
Results
17-AAG inhibits cell cycle in Leishmania spp. promastigotes
We found that 10 µM 17-AAG arrested L. infantum and L. panamensis promastigotes at the G 0 /G 1 phase of cell cycle, as assessed by flow cytometry (Figs. 1A and 1B), which led to a complete growth inhibition (Fig. 1C) . Treatment of Leishmania spp.
promastigotes with 10 µM 17-AAG induced dramatic changes in cell morphology, leading to stubby-shaped bodies, rounding-up, and changes in the flagellum (Fig. 2) .
Following a concentration-response analysis (10 nM -10 µM), we found that incubation with ≥100 nM 17-AAG promoted a concentration-dependent cell cycle arrest at the G 0 /G 1 phase (Table 1) , and morphological changes similar to those described above. Removal of 17-AAG by washing off the drug and subsequent reculture of the cells in drug-free medium for 3 days allowed a partial recovery of the normal cell cycle profile (data not shown).
17-AAG pretreatment sensitizes Leishmania spp. parasites to edelfosine-induced cell death
We have recently reported that the ether phospholipid edelfosine induces cell death in panamensis promastigotes (Table 2 ). These results suggest that 17-AAG facilitates the induction of apoptosis-like cell death mediated by edelfosine.
Discussion
The data reported here indicate that the combined treatment of 17-AAG and edelfosine largely potentiates the killing activity of the ether phospholipid edelfosine on preclinical assays indicate a rather lack of significant toxicity for edelfosine (Gajate et al., 2004; Mollinedo et al., 2010a; Mollinedo et al., 2010b; Mollinedo et al., 2009) Taken together, our present and previous data (Varela-M et al., 2012) indicate that 17-AAG leads to cell cycle arrest and edelfosine promotes an apoptosis-like response in Leishmania spp. The cell cycle arrest, inhibiting cell proliferation, might decrease the probability to render drug resistance, thus potentiating the cell death response triggered by a cytotoxic drug. This could represent a good example of combination therapy, bringing together both cytostatic and proapoptotic agents in the treatment of leishmaniasis. HSP90 protects and stabilizes a wide number of proteins involved in cell survival (Whitesell and Lindquist, 2005 (Petersen et al., 2012) . Our data indicate that 17-AAG at a similar concentration range 
